Progestogens reduce tau phosphorylation via ERK 1/2 in a tau overexpression cell model
Year: 2025
Type: article
Abstract: Several studies have suggested the neuroprotective effects of progestogens in neurodegenerative diseases. Among the most common neurodegenerative diseases are tauopathies. Tauopathies are characterized by the formation of neurofibrillary tangles within neurons, resulting from the aggregation of hyperphosphorylated tau protein, cytoskeleton impairment and, ultimately, cell death. However, the effect of progestogens on those processes needs to be further explored. Thus, this work aims to investigate the effect of progesterone and allopregnanolone on tau hyperphosphorylation in a cellular model of tau overexpression. We used a neuronal cellular model overexpressing the human tau protein (isoform 0N4R) fused with EGFP. The data showed that progesterone effectively decreased the accumulation of overexpressed EGFP-tau. In addition, both compounds reduced tau phosphorylation in different sites, as progesterone reduced at the AT8 and allopregnanolone at AT180 site. The attenuation of its phosphorylation appears to be related to inhibiting the kinase activity of enzymes involved in tau phosphorylation, such as ERK 1/2. Thus, the progestogens tested showed promising neuroprotective potential for the treatment of tauopathies, especially by attenuating hyperphosphorylated forms that give rise to paired helical filaments and neurofibrillary tangles, probably due to modulation of intracellular pathways.
Source: Brain Disorders
Authors: Taysa Bervian Bassani, Rafaela Brito Oliveira, Giulia Ventura Portella, Michelle Sayuri Nishino, Angelica Jardim Costa, Rodrigo Portes Ureshino
Institution: Universidade Federal de São Paulo
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,810
Awards: Evaluation of potential therapeutically compounds for SARS-CoV-2: focus on estrogen-related compounds, autophagy modulators and ACE2, G1220407205, Investigation of mitochondria alterations in in vivo and in vitro models of tauopathies: evaluation of estrogenic compounds treatment, G4154917325, G5312938040, G65531842, G6742486199
OpenAlex ID: W4410458488
